Seegene Launches French Subsidiary to Strengthen European Market Presence

Seegene Inc., a leader in molecular diagnostics, has announced the establishment of a subsidiary in France to enhance its European operations. This move makes France the company's ninth overseas sales subsidiary and its third in Europe, joining Italy and Germany. France is a significant market for molecular diagnostics, especially in sexually transmitted infections, gastrointestinal testing, and respiratory virus detection.

The subsidiary aims to promote wider use of Seegene's developing solutions, CURECA™ and STAgora™, throughout Europe. The French market, with an estimated value of EUR 600 million, is crucial for expanding sales of Seegene's diagnostics products. Local engagement and technical support are expected to accelerate market growth in the region.

Seegene views this strategic expansion as vital for delivering innovative products and understanding the local healthcare landscape. The new setup will support Seegene's global distribution network, which spans 94 countries.